Month: February 2026
-
MSD splits as it stares down Keytruda patent cliff
- Wed Feb 25
Reorganisation of Human Health business sees MSD’s existing business split in two – Oncology, and Specialty, Pharma & Infectious Diseases.
Read more -
TGA chases suspected annual charge dodgers
- Wed Feb 25
With the top 10 beneficiaries receiving more than $77M in forgone charges, the TGA is looking to tighten up its annual exemption scheme.
Read more -
Pharmac looks to fund BMS’ combo neoadjuvant
- Wed Feb 25
Opdivo and Yervoy likely to be funded before surgery for late-stage melanoma patients, providing a new option offering fewer infusions.
Read more -
Less PBS spend doesn’t mean less access: CHF
- Mon Feb 23
Consumers Health Forum investigating whether PBAC submission costs are impacting access, but says falling investment is not of itself a concern.
Read more -
Why Hims & Hers’ Aussie deal concerns all of us
- Mon Feb 23
Eucalyptus pushed TGA boundaries selling GLP-1s for weight loss. Acquired by a US giant that crashed FDA boundaries, what will the deal mean for Australia?
Read more -
Recordati puts a foot down in NZ
- Mon Feb 23
Recordati Rare Diseases has established a permanent footprint in New Zealand and taken on its first employee.
Read more -
Australia’s CGT sector steps into global spotlight
- Mon Feb 23
Cell and Gene Therapy Summit brings global and Australian leaders together to accelerate advanced therapy development, regulatory alignment, and access .
Read more -
Aussie comms star lands global role
- Fri Feb 20
Communications success story Alex Chapman has landed a new senior role just months after leaving Novo Nordisk, and he’s ready for a new adventure.
Read more








